ASH Ends With Consistent Kite CAR-T Data, Some Hope For Juno

The American Society of Hematology annual meeting helped set the stage for what could be the first chimeric antigen receptor T-cell (CAR-T) therapies approved in the US with Kite Pharma Inc. maintaining its spot as a leader in the field, while Juno Therapeutics Inc. continues to face questions about safety.

Kite’s latest data from the ZUMA-1 clinical trial, which is expected to support US FDA approval of the CAR-T therapy axicabtagene ciloleucel (KTE-C19), showed consistent efficacy in aggressive non-Hodgkin lymphoma (NHL) during a Dec. 6 late-breaker session at the end of the ASH meeting in San Diego. Juno’s prospects looked a little brighter as well after data presented on Dec